Novartis' Certican Headed to FDA Advisory Panel in November

Drug Industry Daily
KEYWORDS FDA / NDA
A A

Novartis’ immunosuppressant drug candidate Certican will be reviewed by the FDA’s Cardiovascular and Renal Drugs Advisory Committee Nov. 16. The firm is seeking approval of the drug — in combination with Neoral — for the prevention of rejection episodes following heart or kidney transplantation.

To View This Article:

Login

Subscribe To Drug Industry Daily